tbuckley/cabot-search huggingface dataset:
SAT0527 Quantitative Evaluation of the Shoulder Inflammation in Polymyalgia Rheumatica by Power Doppler Ultrasound
Authors: T. Suzuki, A. Okamoto
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Through the clinical experience of the power Doppler (PD) ultrasound (US) examination of the shoulder lesions in untreated patients with polymyalgia rheumatica (PMR), we noted that there were many cases presenting hyperemia adjacent to the anterior aspect of the subscapularis tendon (hyperemia on SubST). <h3>Objectives</h3> We examined whether the hyperemia on SubST correlates with the disease activity of PMR. <h3>Methods</h3> We analyzed consecutive records of 10 PMR patients and 12 elderly-onset rheumatoid arthritis (EORA) patients mimicking PMR, whose both shoulders were assessed routinely for the hyperemia on SubST using PDUS between July 2010 and September 2012 in our hospital. The areas of PD positive pixels on SubST (PD+ve area) were measured on representative transverse images of the shoulders using Image J (Image analysis software from NIH), and the correlation between the sum of PD+ve area of the bilateral shoulders and various clinical indicators was analyzed. <h3>Results</h3> The mean of the PD+ve area was comparable between PMR group and EORA group. In PMR group, PD+ve area significantly correlated with serum concetration of matrix metalloproteinases (MMP)-3 (|R|=0.886, p= 0.0006). Although weak positive correlation was shown between PD+ve area and serum CRP or erythrocyte sedimentation rate (ESR) in PMR group, it was not statistically significant. There was no significant correlation between PD+ve area and serum MMP-3, serum CRP or ESR in EORA group. <h3>Image/graph</h3> <h3>Conclusions</h3> The strength of the increase in a blood flow adjacent to the anterior aspect of the subscapularis tendon detected by PDUS may serve as an index of a disease activity of PMR, possibly by representing periarticular inflammation. <h3>Disclosure of Interest</h3> None Declared
PRE-MORBID BODY MASS INDEX, HIGH SENSITIVITY TROPONIN-T AND MORTALITY AFTER INCIDENT HEART FAILURE HOSPITALIZATION: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY (ARIC)
Authors: Yashashwi Pokharel, Wensheng Sun, Vijay Nambi, Salim Virani, Scott Solomon, Wenyaw Chan, Ron Hoogeveen, Patricia Chang, Chiadi Ndumele, Elizabeth Selvin, Biykem Bozkurt, Christie Ballantyne, Anita Deswal
Journal: Journal of the American College of Cardiology (2015)
Azygoesophageal fistula: a rare cause of upper gastrointestinal tract bleeding
Authors: G. Gençdal, R. Vardar, H. Bozkaya, C. Meral, M. Parildar, Ö. Özütemiz
Journal: Endoscopy (2013)

A 73-year-old man, who had a history of thoracic aorta aneurysm and aortic valve replacement operations 25 years ago and anemia diagnosed 4 years previously who was currently taking warfarin, propranolol, and iron preparations, presented to the emergency department with melena and hematemesis. His blood pressure was 90/60 mmHg and his heart rate was 108 beats per minute. Investigations showed he had hemoglobin (Hb) of 9 g/dL and an international normalized ratio (INR) of 2.3.
Infants' Gene Therapy Gains Easy RAC Approval
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Infants' Gene Therapy Gains Easy RAC Approval Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 14, 21 July 1993, Pages 1108–1109, https://doi.org/10.1093/jnci/85.14.1108 Published: 21 July 1993
AT-06 * A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Authors: D. Aregawi, T. N. Kreisl, E. Innis, H. A. Fine
Journal: Neuro-Oncology (2014)

BACKGROUND: Preclinical studies indicated that inhibition of NF-kB with bortezemib markedly enhance tamoxifen-mediated glioma apoptosis. A potentially synergistic cytotoxic effect of the combination may benefit patients with malignant gliomas. METHODS: We conducted single institution phase II trial to evaluate efficacy and safety of high dose tamoxifen with bortezomib in adults with recurrent high-grade glioma (HGG). Primary endpoint was radiographic response. Exclusion criteria included concurrent enzyme inducing anticonvulsants and grade ≥2 peripheral neuropathy. Patients received tamoxifen (120 mg PO twice daily) and bortezomib (1.3 mg /m2 of IV on days 3, 6, 10, 13, 24, 27, 31, and 34) of every 6 week cycle. Contrast-enhanced MRI was obtained at the end of each cycle. RESULTS: 42 patients are included in this analysis; 12 anaplastic glioma (AG), 30 glioblastoma (GBM), 32 males, and 10 females. Median age was 39 years (range 28-65) for AG, and 48 years (range 19-68) for GBM. Median KPS at entry was 90 for AG (range 70-100) and 80 for GBM (range 60-100). Median number of prior therapies were 3 (range 1-7). Grade ≥3 treatment related toxicities included lymphopenia (4 pts), hypophosphatemia (3 pts), thromobocytopenia (2 pts), and one instance each of hyponatremia, headache, dyspnea, and DVT. One GBM patient withdrew, two were removed for toxicity, and all others had progression. Among 40 patients evaluable for response, only one achieved stable disease unsustained beyond the first response assessment; all others had rapid progression. Median progression free survival was 5.9 and 5.7 weeks while median overall survival was 25.6 and 14.7 weeks for AG and GBM respectively. The study was closed early due to poor enrollment and therapeutic futility. CONCLUSION: Combination tamoxifen and bortezomib has no activity in this cohort of recurrent HGG. Poor results were likely influenced by poor penetration of bortezomib across blood brain barrier.
CHEMOTHERAPEUTIC TRIALS IN PSYCHOSIS: III. ADDENDUM
Authors: WM. J. TURNER, MANUEL ALMUDEVAR, SIDNEY MERLIS
Journal: American Journal of Psychiatry (1959)

BOL in doses of 10 mg. orally 3 times daily for 4 to 5 weeks was administered to 6 chronically ill schizophrenic women. This abolished the response to LSD up to 200 gamma but failed to alter the psychosis in any way. Initial doses of 10 mg. BOL may produce mild LSD-like reactions.
Abstract 1422: Candesartan-induced Upregulation Of Transcriptional Regulator Yin Yang 1 Blocks Leukocyte-endothelial Interaction Under Physiological Flow.
Authors: Hideto Ishii, Daisuke Mori, Mayuko Sato, Masayuki Yoshida
Journal: Circulation (2007)

[Objective] Transcriptional control of inflammation-relevant genes plays an important role in atherosclerosis. We have reported a dominant role of Yin Yang 1 (YY1), a transcriptional regulator, in proliferation of vascular smooth muscle cells (Santiago FS, Ishii H, et al. Circ Res in press). However, its effect in vascular endothelium remains unclear. Recent observation points a novel “genomic” effect of Angiotensin II to influence inflammation. In this study, we examined a potential contribution of YY1 in angiotensin type II receptor blocker (ARB)-mediated modulation of leukocyte-endothelial adhesion under flow condition. [Methods and Results] Human umbilical vein endothelial cells (HUVEC) were co-incubated in the presence or absence of candesartan, an ARB (1 uM) for 4 hours with TNFα (5 ng/ml). Treatment with candesartan dramatically inhibited THP-1 cell adhesion to TNFα-activated HUVEC under static (p &lt;0.01) and flow conditions (p &lt;0.05). We documented that upregulation of YY1 mRNA after candesartan treatment. To examine a role for YY1 in leukocyte-endothelial interaction, YY1 was overexpressed via recombinant adenovirus. The expression levels of VCAM-1 was significantly decreased in HUVEC treated with adenovirus YY1. In addition, adenovirus YY1 blocked THP-1 adhesion to TNFα-activated HUVEC under flow conditions (TNFα, 8.40±0.64/HPF; TNFα+candesartan, 1.93±0.54/HPF; p &lt;0.0001). The expression level of phosphorylated-JNK, as determined by western blotting analysis, was reduced following YY1 transfection. In contrast, YY1 inhibition by YY1 siRNA did not influence leukocyte-endothelial adhesion and the expression of adhesion molecules. [Conclusion] We demonstrated that candesartan treatment upregulated YY1 in HUVEC and inhibited leukocyte-endothelial adhesion by inhibition of VCAM-1 expression. Our findings suggest a novel anti-inflammatory effect of ARB via YY1-dependent mechanisms.
Website of the week: www.treasury-projects-taskforce.gov.uk/intro/main.htm
Authors: D. Carnall
Journal: BMJ (1999)

This week a paper and an editorial claim that the private finance initiative does not expand the public sector, but drains it of resources. The thinking behind the scheme dates from the Conservative era. You can read what is, in web terms, the ancient history of the schem, from 1992 to 1995, at www.hm-treasury.gov.uk/pub/html/finance95/main.html. New …
Comment on ‘Tumour necrosis factor‐α plays a significant role in the Aldara‐induced skin inflammation in mice’
Authors: L. Grine, C. Libert, R.E. Vandenbroucke
Journal: British Journal of Dermatology (2016)

With great interest we read the recent publication from Vinter and colleagues describing the role of TNFα in the Aldara model 1 .Through the use of scoring skin inflammation, RT-PCR, and histology, they showed that TNFα-deficient mice showed less erythema, scaling, epidermal hyperplasia, Ki67, CD3 + T cells staining and splenomegaly.The authors continued by quantifying several mediating cytokines, such as IL-17A, IL-22, IL-12p40, and IL-23p19; which were significantly reduced in TNFαknockouts.They also quantified interferon regulatory factor (IRF) -7, which on day 1 was clearly elevated in response to Aldara.Similar dynamics and levels were observed in TNFα-knockouts.Therefore, the authors conclude that TNFα does not affect the early type I interferon response.However, we believe this statement is not sufficiently supported by their study and kindly refer the authors to our previous study with TNFR1-knockout mice, which showed a sustained type I interferon response within hours after application 2 .First, we found that IFNα levels in the skin decreased in response to repetitive Aldara treatment.In contrast, TNFR1-knockouts showed steady levels instead.Measurement of IFNα and IFNβ in wild type serum revealed a peak at 3 hours after Aldara, whereas the levels kept increasing in the absence of TNFR1.A similar trend was found in the expression levels of Cxcl10, Ifit2, and Usp18; interferon-responsive genes.We attribute these results to the TNF/TNFR1 pathway negatively regulating type I interferon production in response to Aldara.Since TNFα may act through two different receptors, TNFR1 and TNFR2, it is difficult to interpret results obtained with TNFα-knockout mice only.Yet, similar to the findings of Vinter and coworkers, TNFR1-deficient mice in our study showed reduced IL-12p40 and S100A8 levels.
999 SURVIVAL AND TREATMENT RESPONSES FOR HEPATIC ARTERIAL INFUSION CHEMOTHERAPY IN ADVANCED HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN TUMOR THROMBOSIS
Authors: J.H. Choi, W.J. Chung, E.S. Kim, K.S. Park, K.B. Cho, B.K. Jang, J.S. Hwang
Journal: Journal of Hepatology (2012)
Treatment of Advanced Hodgkin’s Disease with [1,3 Bis (2-Chloroethyl)-1-Nitrosourea] BCNU
Authors: Robert C. Young, Vincent T. DeVita, Arthur A. Serpick, George P. Canellos
Journal: New England Journal of Medicine (1971)

Abstract The nitrosoureas are a new class of antitumor agents that have demonstrated activity against several human tumors. BCNU, a member of this class, was used to treat 45 patients with far adva...
PTH-173 Introduction of the Team Brief and who Safety Checklist in Endoscopy
Authors: S Vinnamala, B Disney, I Mohammed, W Chapman, E Fogden
Journal: Gut (2013)

<h3>Introduction</h3> The World Health Organization (WHO) launched the Global Patient Safety Challenge, ‘Safe Surgery Saves Lives’<sup>1</sup>, in 2008 with the aim of reducing the number of deaths and adverse events resulting from surgical procedures. Central to this initiative is the WHO checklist that covers the various phases of a procedure. This checklist was modified and used for all endoscopic procedures performed in our trust. <h3>The Aim</h3> of the survey was to gather opinions from endoscopy staff about the recently introduced team debrief and the modified WHO checklist for endoscopy in our trust. We aimed to assess the staff’s perception of the impact of the checklists (positive or negative) on patient safety, communication and team behaviour, staff satisfaction and their general effectiveness. We also aimed to assess the need for training on the use of the checklists and their potential to drive improvement with an additional section for their comments. Responses were obtained from the different grades of staff including nurses, health care assistants, trainees and consultants. <h3>Methods</h3> We designed a questionnaire according to the LIKERT2 scale, where the respondent could choose between five options including one neutral stance and the other four with varying degrees of agreement or disagreement with sixteen questions covering the above mentioned key categories. Participation in the survey was anonymous and voluntary. <h3>Results</h3> 78 staff across two hospitals of the trust responded to the survey, of which two were incomplete and hence excluded from analysis. Respondents included consultants (20), Specialist Registrars (8), nurses (29), health care assistants (12) and unknown (7). 81% perceived an improvement in patient safety and 75% in team communication. 75% were satisfied with the checklists. 80% believed that the checklists have the potential to drive improvement with 96% of them wanting to continue using these. The only negative aspect from the survey was that almost a half of the respondents (48%) felt that their feedback was not acted upon. 100% agreed that all staff needed to participate actively in the checklist and team briefs. <h3>Conclusion</h3> Our results suggest that the introduction of the adapted WHO checklist has been a positive experience based on this staff survey, enhancing patient safety and staff communication. This adapted checklist will continue to evolve based on staff feedback. We suggest that all endoscopy units should introduce an adapted WHO checklist and we understand that the BSG is developing one currently. <h3>Disclosure of Interest</h3> None Declared. <h3>References</h3> Safe Surgery Save Lives - WHO/IER/PSP/2008.07 Public Opinion and the Individual. Gardner Murphy and Rensis Likert. New York: Harper &amp; Brothers, 1938
Case 25-1992
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, J.M. Seidman, E.J. Mark
Journal: New England Journal of Medicine (1992)

Presentation of CaseA 33-year-old woman with hepatic and respiratory failure was admitted to the hospital for consideration of liver and lung transplantation.The patient was well until seven years earlier, when right-upper-quadrant pain with enlargement of the liver developed. Results of liver-function tests were abnormal. Examination of a biopsy specimen of the liver showed granulomatous hepatitis consistent with sarcoidosis; there was no evidence of cirrhosis. The patient received prednisone for one month. She felt well and worked as a professional dancer until five months before entry, when she became fatigued and dyspneic while dancing. The dyspnea worsened until she . . .
PWE-011 Charting the Volatile Organic Metabolome (VOM): A Comparison of Murine and Human Faeces
Authors: D Sawbridge, S Reade, T Khalid, C Probert
Journal: Gut (2013)

<h3>Introduction</h3> The metabolome is important in the development of IBD and colorectal cancer. It may be studied using gas chromatography mass spectrometry (GCMS) or electronic noses that sniff the volatile organic compounds, which comprise a large portion of the metabolome. However the healthy volatile organic metabolites (VOMs) of mice remain uncharted, nor have mouse models been validated for use in comparative studies of VOMs with humans. <h3>Methods</h3> We collected serial samples from healthy C57 BL/6 mice and a healthy human, as part of our method development for VOM studies in colitis and colorectal cancer. The samples were enclosed in glass vials and the VOMs extracted from the headspace gas. VOMs were analysed using GCMS and the resultant fragmentation patterns compared to the NIST database for compound identification. VOMs from murine and human samples were compared. The consistency of mouse and human samples over time and between individuals was also examined by listing the rank position in quintiles over serial samples. <h3>Results</h3> 60 individual VOMs were identified from mice and 87 in the human, with a 22% correlation between the two. Most notable in the murine sample was the high concentration of simple organic molecules such as hexane and short chain aldehydes. Several compounds were found in the murine sample that had not been seen in human samples and probably reflect urine contamination from incontinent mice. The greatest concentration of VOMs in the mouse were: hexanal, 2.2.4.6.6-pentamethyl-heptane and pentanal. By comparison, in the human, complex cycloalkenes and benzene-based compounds, such as 1-methyl-4-(1-methylethylidene)-cyclohexene, were in abundance. Chief compounds in the human were: D Limonene, 2-methyl phenol and indole. Several molecules were prominent in both mouse and human, such as acetone, short chain organic acids including hexanoic, pentanoic and butanoic acids and D-limonene. The more simple compounds likely reflect a combination of the metabolic effluvia of common intestinal microbiota and mammalian physiology. The position of VOMs in each quartile was found to be consistent with 86% recurrence in the first quartile, 71% in the last quartile. <h3>Conclusion</h3> This is the first description of the VOC metabolome of C57 BL/6 mice. A comparison with human samples shows there is a low but notable correlation between the two species. Many of the VOCs present are by-products of microbial and cellular metabolism. The difference in number and complexity of the VOCs found in the human, compared with the mouse, may reflect varied diet and a more complex intestinal microbiome. Such data will allow calibration of future studies of colonic disease in humans and through the induction of colonic disease in mice. <h3>Disclosure of Interest</h3> None Declared.
PD-014 First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)
Authors: F Rivera, M. Karthaus, J.R. Hecht, G. Fasola, J.-L. Canon, R. Koukakis, G. Demonty, L. Schwartzberg
Journal: Annals of Oncology (2015)
MRI and FDG PET/CT Findings in 3 Cases of Spinal Infectious Arachnoiditis
Authors: Aisheng Dong, Changjing Zuo, Ping Zhang, Jianping Lu, Yushu Bai
Journal: Clinical Nuclear Medicine (2013)

Spinal arachnoiditis is a disease characterized by inflammation and scarring of the arachnoid membrane of the spinal cord. FDG PET/CT findings of spinal arachnoiditis have been rarely reported. We present 3 cases of spinal infectious arachnoiditis (1 pyogenic and 2 tuberculous). MRI was performed in these 3 cases showing thickened spinal meninges with marked enhancement. FDG PET/CT was performed in 2 cases showing intense linear FDG uptake along the spinal canal. The combination of MRI and FDG PET/CT may be helpful in identifying the infectious sites and evaluating the activity of the infection.
AB0405 No decrease in bone mineral density when prednisone is added to a methotrexate-based tight control strategy for early rheumatoid arthritis
Authors: M.C. van der Goes, J.W. Jacobs, M.S. Jurgens, M.F. Bakker, P.M. Welsing, J.W. Bijlsma
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To describe effects on bone mineral density (BMD) of 10 mg prednisone daily in patients with early rheumatoid arthritis (RA), who were treated according to a methotrexate-based tight control strategy and received preventive therapy for osteoporosis. <h3>Methods</h3> Early RA patients were included in the CAMERA-II trial: a randomized, placebo-controlled, double-blind two-year trial, in which the effects of addition of 10 mg prednisone daily to a methotrexate-based tight control strategy were studied. All patients received calcium, vitamin D, and a bisphosphonate. Disease activity was assessed every four weeks. X-rays of hands and feet and dual-energy X-ray absorptiometry of lumbar spine and left hip were performed at baseline, and at one and two years of treatment. <h3>Results</h3> The standardized BMD (sBMD) increased significantly over time in both treatment groups in the lumbar spine (p&lt;0.001), but not in the hip; at none of the time points sBMD differed significantly between the prednisone and placebo group. Higher age and lower weight at baseline, and higher disease activity scores during the trial, but not glucocorticoid therapy, were associated with a lower sBMD at the lumbar spine as well as the hip in mixed model analyses. <h3>Conclusions</h3> Addition of 10 mg prednisone daily from start of therapy to a methotrexate-based tight control strategy does not lead to bone loss in early RA patients on adequate preventive treatment for osteoporosis. A small increase in lumbar BMD during the first year of treatment was found, regardless of the use of glucocorticoids. <h3>Disclosure of Interest</h3> None Declared
Treatment of Patients with Cancer of an Unknown Primary Site
Authors: Alastair J.J. Wood, John D. Hainsworth, F. Anthony Greco
Journal: New England Journal of Medicine (1993)

Few diagnoses in medicine engender as much pessimism as the diagnosis of metastatic cancer of an unknown primary site. Patients with this syndrome often have widespread metastatic disease, with involvement of multiple visceral sites such as the liver, lungs, and bones, and are often debilitated at the time of diagnosis. Early reports of chemotherapy in these patients documented low rates of response and no effect on the dismal median survival of three to four months, thereby strengthening arguments for a nihilistic approach14.Recently, however, the treatment of some patients with cancer of an unknown primary site has improved . . .